Danaher Raises Dividend, Acquires Masimo for $9.9B Amid Life Sciences Profit Decline
Danaher approved a $0.40 quarterly dividend and completed a $9.9 billion Masimo acquisition to expand into patient monitoring, while its Life Sciences segment operating profit fell 57% in 2025 to $520 million.
Danaher Corporation's Board approved a regular quarterly cash dividend of US$0.40 per share, paid on April 24, 2026 to shareholders of record on March 27, 2026. The US$0.40 dividend follows a US$0.32 payout declared in December 2025. The company also presented at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026.
Danaher's $9.9 billion acquisition of Masimo has repositioned the life sciences giant toward patient monitoring, sending DHR shares down roughly 3% to $206 on February 17 as investors questioned whether the deal represents a strategic pivot or an admission that core biotech growth remains constrained. Analysts flagged the acquisition as "unexpected," warning that the shift toward patient-monitoring equipment could pressure shares in the near term.
Driving the deal's logic is Masimo's commanding position in pulse oximetry, its strong recurring-revenue base, and a projected $125 million in combined cost synergies, with Danaher expecting a $0.2 EPS boost in the first full year after close and approximately $0.7 in year five. The Masimo deal broadens Danaher's Diagnostics segment by pairing invasive Radiometer blood analyzers with Masimo's non-invasive pulse oximeters and brain function monitoring devices.
The company's President and CEO stated on the Q4 earnings call that "the combination of our differentiated portfolio, the power of the Danaher Business System and the strength of our balance sheet positions Danaher for long-term value creation as we move into 2026 and beyond," contextualizing remarks delivered just weeks before the company's largest acquisition since its $5.7 billion Abcam deal in 2023.
The most consequential near-term risk sits in Danaher's Life Sciences segment, where operating profit already collapsed 57.0% in 2025 to $520 million. Danaher's revenue grew 2.9% in 2025 and analysts project 4.4% growth in 2026, while normalized EPS climbs from $7.8 to an estimated $8.4, a 7.8% jump that reflects both operational leverage and the $0.2 first-year EPS contribution Masimo is expected to deliver.
Third Point raised its Danaher stake nearly 12x, from 50,000 to 600,000 shares as of December 31. Wall Street stands firmly behind the name with 18 buys, 4 outperforms, and just 3 holds against zero sells, converging on a mean price target of $264.9 that implies 26.4% upside from the current $209.5. The spread between the $220.0 low target and $310.0 high target reflects a genuine fork in the road, where the bear scenario prices in deal integration risk and multiple compression while the bull case demands successful Masimo execution plus a full bioprocessing equipment recovery.
Danaher's narrative projects $29.2 billion revenue and $5.7 billion earnings by 2028. This requires 6.7% yearly revenue growth and a roughly $2.3 billion increase in earnings from $3.4 billion today. The next quarterly earnings report is scheduled for release on Tuesday, April 28, 2026.
The company's performance is fundamentally linked to demand for tools utilized in pharmaceutical research and clinical applications. A primary gauge for organic growth is considered to be the performance of consumables for bioprocessing technology. Furthermore, the business environment is directly shaped by worldwide trends in healthcare spending and the distribution of research grants.